CellPath signs exclusive agreement with US-based Biocare Medical
Newtown headquartered CellPath, a manufacturer and worldwide supplier of products, consumables and services to aid in cancer diagnostics, has secured the signature of Biocare Medical LLC to become its exclusive distributor in the UK.
Biocare is a major US innovator, becoming the market leader in the development of simultaneous Multiplex Immunohistochemistry tests that provide increased confidence at critical diagnostic decision points, positively impacting patient therapy while accelerating turnaround time.
The agreement will take effect from June 1 and should bring significant growth and job expansion to CellPath.
Philip Webber, joint managing director at CellPath, said: “This is a very exciting opportunity for the company, and we’re delighted that our recent results have given Biocare the confidence to choose us as their best route into the UK market.
"This opportunity will bring further success to CellPath and lead to additional recruitment for the local market. As a family-business whose roots are based here in mid-Wales, we are delighted with the progress we’ve made, we certainly have an exciting future thanks to the skill, determination, cooperation and loyalty of the CellPath team. We’ve come a long way.”
Jonas Falgen, Biocare Medical’s sales director for Europe, added: “CellPath are the market leading cellular pathology company in the UK, so it was an easy chose to ask them to undertake our distribution in the UK. They have proven success dating back many years and demonstrated to us that our products are in very safe hands. I’m sure this is the beginning of a fruitful and mutually beneficial partnership.”
